 Home > Active Ingredient News > Immunology News > Eur Heart J: Anti-interleukin-1 drugs for the treatment of pericarditis

Eur Heart J: Anti-interleukin-1 drugs for the treatment of pericarditis

 Last Update: 2021-09-29
 Source: Internet
 Author: User

Tags

famotidine side effects

protein 1

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Anti-interleukin (IL)-1 drugs have been developed to treat auto-inflammation and rheumatism, where excessive production of IL-1 is an important pathophysiological process
.

IL-1α and IL-1β are the most studied members of the IL-1 cytokine family and have the strongest pro-inflammatory effects

Recently, cardiac vascular areas authoritative magazine Eur Heart J published a research article, the study aims to provide information on the use of anti-IL-1 drug therapy pericarditis guidance, including their historical background as a clinician, how they are developed , Their mechanism of action, dosage, side effects and usage techniques
.

Heart blood vessels

Currently, there are three clinically available anti-IL-1 drugs: Anakinra (recombinant human IL-1Ra), Linacipr (a soluble decoy receptor "trap" that binds IL-1α and IL-1β) And Kananumab (human monoclonal anti-IL-1β antibody)
.

For patients with corticosteroid-dependent and colchicine-resistant recurrent pericarditis, there is evidence of systemic inflammation, such as elevated C-reactive protein, anakinra (2mg/kg/day to 100mg/day subcutaneous injection, usually At least 6 months, and then gradually reduce) and lilocept (320 mg subcutaneously on the first day, then 160 mg subcutaneously every week), the efficacy and safety have been confirmed in observational studies and randomized controlled clinical trials
.

Severe side effects are rare, and the discontinuation rate is very low (<4%)

It can be seen that anti-IL-1 drugs seem to be the most important development in the treatment of recurrent pericarditis in the past 5 years
.

Anti-IL-1 drugs seem to be the most important development in the treatment of recurrent pericarditis in the past 5 years
.

Original source:

Massimo Imazio.

Anti-interleukin-1 agents for pericarditis: a primer for cardiologists leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

High Purity 99% BPN14770 Zatolmilast 1606974-33-7 In Stock Fast Ship to USA

CAS No.: 1606974-33-7

Pharm Grade

$1-1.1/UNIT FOB

High quality Thymosin α1 Pure CAS 62304-98-7 Thymosin Alpha 1 Thymalfasin

CAS No.: 62304-98-7

Pharmacy Grade

$12-15/UNIT FOB

Top quantity Imiquimod CAS NO 99011-02-6 White crystalline powder 99% API

CAS No.: 99011-02-6

Pharmacy Grade

$1800-1850/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.